Please login to the form below

Not currently logged in
Email:
Password:

AbbVie expects Humira to drive growth in inaugural guidance

First statement since split from Abbott

AbbVie

AbbVie gave its first financial guidance since spinning out from Abbott Laboratories, predicting 2013 earnings per share in the $3.03-$3.13 range, in line with analyst forecasts.

The company also said its flagship Humira (adalimumab) product for rheumatoid arthritis grew 17 per cent last year to $9.27bn, making it the world's top-selling drug, although it is expecting 2013 growth to be in the low double digits.

Humira also treats Crohn's disease and psoriasis and is expected to be the engine driving AbbVie for the foreseeable future, but it is already facing competition from a new generation of oral anti-inflammatory therapies such as Pfizer's Xeljanz (tofactinib citrate).

Added to that, it is due to start losing patent protection in 2016, although AbbVie says there is still plenty of upside in the brand from new indications and expansion of sales in emerging markets.

The onus is now on AbbVie to bring multiple new products to market in the next two to three years to help build a revenue platform when Humira starts to wane.

AbbVie's chairman and chief executive Richard Gonzalez highlighted the progress with AbbVie's hepatitis C pipeline as one of the key achievements of 2012, along with the performance of the firm's speciality medicines.

Top of the list in the speciality division is testosterone replacement therapy AndroGel – 31 per cent to $1.15bn in 2012 – with support from Creon (pancrelipase) for pancreatic insufficiency and hypothyroidism treatment Synthroid (levothyroxine), both up around 6 per cent to $353m and $551m, respectively.

AbbVie is vying with other drugmakers including Gilead Sciences, Bristol-Myers Squibb and Boehringer Ingelheim to bring the first all-oral, interferon-free hepatitis C regimen to market.

Meanwhile, the company's mid-to late-stage pipeline also includes drugs for kidney disease, multiple sclerosis, endometriosis, chronic lymphocytic leukaemia and multiple myeloma.

AbbVie said it expects its pipeline to start making a significant contribution by the second half of 2015.

1st February 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....

Infographics